Andrew E. Aplin, PhD

My research elucidates mechanisms underlying aberrant growth and invasion in different subsets of melanoma.  Initially, we identified targets of mutant BRAF signaling and showed their contribution to malignant traits in BRAF V600E melanoma. Additionally, we have characterized the determinants of response and mechanisms of resistance to BRAF, MEK and CDK4/6 inhibitors and the influence of the tumor micro-environment.  To facilitate these efforts, we have developed novel models to quantitatively measure signaling pathways in melanoma tumors in vivo.  An important approach that we take is to analyze the effects of targeted inhibitors and epigenetic inhibitors on the immune tumor microenvironment.  In team-based approaches, we are studying ocular/uveal melanoma to complement clinical strengths at my institution.

I serve roles at both the institutional and national level. At Thomas Jefferson University, I am the Associate Director for Basic Research in the NCI-designated, Sidney Kimmel Comprehensive Cancer Center. In this position, I oversee the basic science programs, recruitment and pilot awards.  I also serve as the Program Leader for the Cancer Cell Biology and Signaling (CCBS) program. Nationally, I am a regular member for the Molecular Cancer Therapeutics 1 (MCT1) study section. Previously, I have served as a regular member of the NIH study section, Tumor Microenvironment (TME), Discussion Leader on NCI SPORE review panels and Chair for American Cancer Society Cell Structure and Metastasis (CSM) committee.  I also serve on the Scientific Advisory Council (SAC) for the Melanoma Research Foundation and the Steering committee for the Society for Melanoma Research. I am a former Associate Editor of Pigment Cell and Melanoma Research (2013-2017) and currently serve on the editorial board of Cancer Research and Molecular Cancer Research.